Day: March 2, 2026

Norwegian Cruise Line Holdings Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided guidance for the first quarter and full year 2026. HighlightsGrew total revenue 3.7% to $9.8 billion in 2025. GAAP net income was $423.2 million, with EPS of $0.92. Delivered Adjusted EBITDA1 of $2.73 billion in 2025, exceeding guidance, and representing an increase of 11% compared to 2024. Adjusted Net Income grew 15% to $1.045 billion. Adjusted EPS grew 19% to $2.11. Company sets full year 2026 guidance with Adjusted EPS expected to be $2.38. Company completed first phase of enhancements to Great Stirrup Cay, the...

K92 Mining Announces 2025 Q4 and Annual Financial Results – Record Annual Net Cash Balance, Revenue, Net Earnings, Operating Cash Flow and EBITDA; Annual Production at Upper Half of Guidance, Cash Cost and AISC Better Than Guidance

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three and twelve months ended December 31, 2025. ProductionFourth Quarter 2025Strong quarterly production of 47,178 ounces gold equivalent (“AuEq”)(1) or 44,129 oz gold, 1,940,781 lbs copper and 47,427 oz silver. Cash costs of US$768/oz gold, and all-in sustaining costs (“AISC”) of US$1,619/oz gold (3). Record quarterly ore processed of 186,198 tonnes, a 93% increase from Q4 2024, with a head grade of 8.0 grams per tonne (“g/t”) AuEq, or 7.4 g/t gold, 0.5% copper and 10 g/t silver, with a moderate positive gold and copper grade reconciliation versus the latest independent mineral resource estimate (September 12, 2023 effective date for Kora and Judd). Strong...

RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024 Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of 2024 Total Company Adjusted EBITDA(1) margins increased by 29 bps to 16.0% in the fourth quarter of 2025 as compared with 15.7% in the fourth quarter...

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026 Completed enrollment in the Phase 2/3 DRAGON II trial in STGD1 Completed a $402 million underwritten public offering of American Depositary Shares Conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ETSAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its preliminary, unaudited financial results for the fourth...

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026 Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and China Additional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J) $62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program $250.0 million non-recourse royalty-backed note financing from Royalty Pharma to provide non-dilutive capital to support the ongoing stock repurchase program, potential strategic...

Danish Ship Finance A/S appoints new CCO

Written by Customer Service on March 2, 2026. Posted in Public Companies.

Danish Ship Finance A/S appoints new CCOAttachmentNo. 4 – Danish Ship Finance appoints new CCO

TRX Gold Reports Record Q2 2026 Production and Company Update

Written by Customer Service on March 2, 2026. Posted in Public Companies.

TORONTO, March 02, 2026 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) is pleased to announce preliminary results for Q2 20261 as well as a significantly improved capital structure following the exercise of share purchase warrants (“warrants”) of the Company during the quarter. Unless otherwise noted, all references to currency in this press release refer to US dollars. Stephen Mullowney, TRX Gold CEO commented: “We’re very pleased with the positive trajectory and record gold production achieved at Buckreef Gold this quarter as the Company continued to benefit from access to higher grade ore and improved mill recoveries following our recent process plant upgrades. The record production and leverage to record gold price levels enabled the Company to continue to strengthen its...

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Written by Customer Service on March 2, 2026. Posted in Public Companies.

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceased Proceeds strengthen Zymeworks’ balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide...

Information on share capital and voting rights – February 2026

Written by Customer Service on March 2, 2026. Posted in Public Companies.

Information on share capital and voting rights February 2026 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. March 2nd, 2026 Statement made by: Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)Date Total number of shares Total number of voting rightsTheorical (1) Exercisable (2)February 27th, 2026 43,744,779 43,744,779 43,610,950(1) Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2) For information, excluding treasury shares stripped of voting rights, excluding liquidity contract. Provision of Nexans articles of association...

RadNet Acquires Gleamer, Making RadNet’s DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

Written by Customer Service on March 2, 2026. Posted in Public Companies.

Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications. Gleamer’s leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer’s solutions will provide the industry’s most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue (“ARR”) i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 million ARR in 2026. The acquisition will augment DeepHealth’s global commercial sales force and add a strong research and development team who have developed,...

Day: March 2, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals